Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema

American Journal of Ophthalmology
J B JonasI Akkoyun

Abstract

To evaluate the duration of the effect of intravitreal triamcinolone acetonide on visual acuity in patients with diffuse diabetic macular edema. Clinical interventional case series. Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg triamcinolone acetonide. Mean follow-up time was 13.2 +/- 6.0 months (6.03-25.2 months). Visual acuity and intraocular pressure began to increase significantly (P =.003) within the first week, reaching a plateaulike maximum at 1 to 7 months postinjection, returning to baseline values 8 to 9 months postinjection. The effect of an intravitreal injection of approximately 20- to 25-mg triamcinolone acetonide in patients with diffuse diabetic macular edema lasts approximately 7 to 8 months. This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema.

References

Sep 1, 2001·American Journal of Ophthalmology·J B Jonas, A Söfker
May 3, 2002·Ophthalmology·Adam MartidisCaroline Baumal

❮ Previous
Next ❯

Citations

May 26, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·I KreissigJ B Jonas
Jul 22, 2005·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Remzi Avci, Berkant Kaderli
Aug 20, 2011·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Norihito DoiTatsuro Ishibashi
Jun 8, 2007·Japanese Journal of Ophthalmology·Yuka ShimonaganoTaiji Sakamoto
Jul 31, 2007·Japanese Journal of Ophthalmology·Yuka ShimonaganoTaiji Sakamoto
Feb 19, 2008·The Kaohsiung Journal of Medical Sciences·Yo-Chen Chang, Wen-Chuan Wu
Jul 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jost B JonasUrs Vossmerbaeumer
Jul 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jost B JonasUlrich H M Spandau
Jul 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Lan-Hsin ChuangChi-Chun Lai
Apr 23, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ryosuke KawamuraKazuo Tsubota
Jul 9, 2009·Retina·Gholam A PeymanDarius M Moshfeghi
Dec 24, 2004·The British Journal of Ophthalmology·J B JonasB A Kamppeter
Jul 19, 2005·The British Journal of Ophthalmology·U H M SpandauJ B Jonas
Jul 19, 2005·The British Journal of Ophthalmology·S A Vernon
Apr 7, 2006·The British Journal of Ophthalmology·D J RheeM R Moster
May 19, 2006·The British Journal of Ophthalmology·C K M ChanD S C Lam
Jul 21, 2006·The British Journal of Ophthalmology·M D Conway
Aug 25, 2006·The British Journal of Ophthalmology·A Longo
Sep 2, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Akira WatanabeHiroshi Tsuneoka
Jan 22, 2008·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Yumiko YamamotoHisayuki Ueno
Mar 20, 2008·Survey of Ophthalmology·Matthew A CunninghamShalesh Kaushal
Aug 28, 2007·Survey of Ophthalmology·C M JermakG A Peyman
Sep 18, 2007·American Journal of Ophthalmology·Nicola G GhaziJulia A Haller
May 1, 2007·Ophthalmology·H Richard McDonaldUNKNOWN Ophthalmic Technology Assessment Committee Retina Panel
May 1, 2007·The Veterinary Journal·José M MolledaEva M Martín-Suárez
Aug 26, 2009·Clinical & Experimental Ophthalmology·Shaheeda MohamedDennis S C Lam
Aug 26, 2006·Journal of Cataract and Refractive Surgery·Yi-Sheng ChangMei-Feng Chen
Mar 28, 2006·American Journal of Ophthalmology·John T Thompson
Oct 18, 2005·American Journal of Ophthalmology·Teresio AvitabileAlfredo Reibaldi
Jul 12, 2005·Progress in Retinal and Eye Research·Jost B JonasRobert Degenring
Sep 19, 2006·American Journal of Ophthalmology·François AudrenPascale Massin
Jun 15, 2005·American Journal of Ophthalmology·Wai-Man ChanDennis S C Lam
Feb 3, 2006·Clinical & Experimental Ophthalmology·Remzi AvciFatma D Akalp
May 6, 2014·American Journal of Ophthalmology·Michael S KovalMichael J Pro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.